GSK advises supply of new quadrivalent (four-strain) influenza vaccine, Fluarix® Tetra, recently launched in Australia and available for private sale, is no longer available for the remainder of the 2015 influenza season due to high levels of demand.
These press releases are intended for business journalists and analysts/investors
In 2014, GSK Australia made payments totalling $3,466,951 to healthcare professionals (HCPs) and health-related organisations (HCOs) for grants, sponsorships and consultancy fees related to chairing and speaking at meetings, assistance with training and participation in advisory boards.
Learn more about how we are making our vaccines more accessible in developing countries
More children from the world’s poorest countries are being vaccinated against more diseases than ever before.
GSK provides £50,000 donation to Save the Children to support relief efforts following Tropical Cyclone Pam.
GlaxoSmithKline plc (LSE/NYSE: GSK) announces that its three-part transaction with Novartis has completed today.
MELBOURNE, AUSTRALIA and MUMBAI, INDIA, 3 March, 2015 - GlaxoSmithKline (GSK) and Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE:524715, “Sun Pharma”) today announced that their respective wholly owned subsidiaries have reached an agreement related to GSK’s Opiates business in Australia.
Regrettably, Zovirax Ophthalmic Ointment (aciclovir 3%) continues to be impacted by a global supply constraint and is unlikely to be available in Australia prior to September 2015.
More children from the world’s poorest countries are being vaccinated against more diseases than ever before. This is a good thing and has been made possible by unprecedented cooperation between governments, NGOs and pharmaceutical companies.
GSK has responded to the South Australian bushfire emergency by providing eight pharmacies in the Adelaide Hills fire affected areas with a donation of asthma rescue medicine. This donation is being managed in partnership with Asthma Foundation SA and the Pharmacy Guild of Australia.
Incruse® Ellipta® (umeclidinium) to be reimbursed in Australia for Chronic Obstructive Pulmonary Disease
- Reimbursed via the Pharmaceutical Benefits Scheme from 1st December
- Administered using a new dry powder inhaler called Ellipta1
We are one of the world’s largest science-led pharmaceutical and healthcare companies. Each year we research, manufacture and sell innovative medicines, vaccines and healthcare products for millions of people across the world, helping them to do more, feel better and live longer.